Morgan Stanley raised the firm’s price target on NeuroPace to $9 from $8 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NPCE:
- NeuroPace price target raised to $12 from $10 at Lake Street
- Lake Street medical devices analysts hold an analyst/industry conference call
- NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
- NeuroPace price target raised to $8 from $6 at Morgan Stanley
- NeuroPace initiated with an Overweight at Cantor Fitzgerald
Questions or Comments about the article? Write to editor@tipranks.com